Poor
Not Aligned
Patient Risk:
Moderate
Summary
Indication-related claims align with the provided FDA label excerpts, but multiple adverse-effect and generic/patent/economics claims are unsupported by the supplied label text, and key safety domains (contraindications, boxed warnings, pregnancy risk, pediatric safety, drug interactions) were not supported by provided label citations.
Category Scores
Accurate Statements
Cozaar is the brand name for losartan potassium.
11 DESCRIPTION (COZAAR (losartan potassium))
Cozaar is an angiotensin II receptor blocker (ARB).
11 DESCRIPTION (acting on the AT1 receptor; angiotensin II receptor blockade)
Cozaar is used to treat high blood pressure (hypertension).
1.1 Hypertension (indicated for treatment of hypertension)
Cozaar is used to help protect the kidneys in people with type 2 diabetes who have high blood pressure.
1.3 Nephropathy in Type 2 Diabetic Patients (diabetic nephropathy with history of hypertension; reduces progression)
Cozaar is used to reduce the risk of stroke in certain patients with high blood pressure and left ventricular hypertrophy.
1.2 Hypertensive Patients with Left Ventricular Hypertrophy (reduce risk of stroke; benefit not apply to Black patients)
Unsupported Statements
Common side effects of Cozaar may include dizziness.
No adverse-reaction/side-effect content supporting this specific example was provided in the supplied label excerpts.
Common side effects of Cozaar may include fatigue.
No adverse-reaction/side-effect content supporting this specific example was provided in the supplied label excerpts.
Common side effects of Cozaar may include upper respiratory tract infection.
No adverse-reaction/side-effect content supporting this specific example was provided in the supplied label excerpts.
More serious side effects of Cozaar are rare but can include kidney problems.
No provided label excerpt supports the 'rare' framing or the specific 'kidney problems' serious-side-effect claim.
More serious side effects of Cozaar are rare but can include severe allergic reactions.
No provided label excerpt supports the 'rare' framing or the specific 'severe allergic reactions' claim.
Generic losartan potassium is approved by the FDA.
Not supported by any provided prescribing information excerpt (and this is not a labeling claim contained in the supplied sections).
Generic losartan potassium has the same active ingredient, dosage form, strength, and route of administration as Cozaar.
Not supported by the supplied prescribing information excerpts.
Generic losartan potassium is generally less expensive than the brand-name version.
Not a labeling claim in the supplied prescribing information; economics not addressed.
The original patents for Cozaar have long since expired.
Not supported by the supplied prescribing information excerpts.
Drug patent expiry dates determine when generic versions can enter the market.
Not supported by the supplied prescribing information excerpts.
Contradictions
Important Omissions
Contraindications were not addressed in the AI-generated claims, despite contraindications being present in the provided label excerpts (hypersensitivity; coadministration with aliskiren in patients with diabetes).
Importance:
Moderate
Boxed warning (fetal toxicity) and pregnancy discontinuation guidance were not addressed in the AI-generated claims, despite being present in the provided label excerpts.
Importance:
Moderate
Pediatric use limitations were not addressed in the AI-generated claims, despite pediatric use being present in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI response includes multiple unsourced adverse-effect claims and omits key on-label safety elements (contraindications, boxed warning/pregnancy, pediatric limitations) from the label excerpts provided, limiting reliability for safety-critical counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Adverse-effect and generic/patent/economic claims are not supported by the supplied FDA prescribing information excerpts; key safety domains were omitted.
Suggested Improvement
Remove or replace unsupported side-effect and non-label claims; restrict statements to sections provided in the FDA label excerpts (Indications, Contraindications, Warnings/Precautions, and listed labeled population information) or cite the corresponding label sections for each safety-related claim.